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Abstract
Introduction: Inflammatory processes have previously been shown to influence cognition and progression of dementia.
An involvement of interleukin (IL)-6 has in particular been suggested as altered levels of IL-6 in cerebrospinal fluid (CSF)
have been found in patients with Alzheimer’s disease (AD). Also, an association between cognitive decline and levels of
IL-6 in CSF have been reported. The aim of the present study was to investigate whether patients clinically diagnosed
with dementia with Lewy bodies (DLB) display altered CSF IL-6 levels in comparison with patients with AD and control
subjects without dementia and whether the IL-6 levels are correlated with cognitive status and biomarkers for AD and
synucleinopathy.
Methods: To analyse CSF of patients with AD (n = 45), patients with DLB (n = 29) and control subjects without
dementia (n = 36), we used immunoassays to measure levels of IL-6 (multiplex electrochemiluminescence); AD
markers phosphorylated tau, total tau and amyloid-β1–42 (enzyme-linked immunosorbent assay [ELISA]); and α-synuclein
(ELISA). Cognitive status was evaluated using the Mini Mental State Examination (MMSE).
Results: Our analysis showed significantly lower levels of IL-6 in CSF from patients with DLB than in CSF from patients
with AD and control subjects without dementia. The IL-6 levels were also negatively correlated with MMSE and positively
correlated with α-synuclein CSF levels.
Conclusions: Our findings support previous studies by demonstrating a link between inflammatory processes and
dementia progression and further strengthen the hypothesis that IL-6 is involved in dementia pathology and cognitive
decline.
Introduction
Glial secretion of interleukin-6 (IL-6), along with other
pro- and anti-inflammatory cytokines and chemokines,
is drastically increased in response to infection or harm-
ful changes in the brain. The increase in IL-6 secretion
has been shown to be beneficial [1–5], but sometimes
also detrimental [6–9], for the neuronal network, de-
pending on variables such as cytokine concentration,
brain region, target cell and developmental stage. The
impact of IL-6 on neuronal network formation and func-
tion is noticeable in a number of in vivo rodent studies.
For example, foetal exposure to IL-6 has been shown to
alter rat hippocampal structure and impair spatial learning
[10], and deficiency of IL-6 has been shown to improve
long-term memory [11] and lipopolysaccharide-induced
impairment of working memory [12]. Also, results of clin-
ical studies point towards a relationship between IL-6 and
brain function, as cognitive decline has been associated
with elevated levels of IL-6 in plasma and/or serum
[13–16] and cerebrospinal fluid (CSF) [17, 18].
Given the role of IL-6 in neuroinflammatory actions
and its potential impact on cognitive function, it is not
surprising that IL-6 secretion has been found to be al-
tered in neurodegenerative dementia disorders linked to
neuroinflammation. Examinations of post-mortem brain
tissue from patients with Alzheimer’s disease (AD) have
revealed activated glial cells as well as elevated expres-
sion of IL-6 adjacent to amyloid-β (Aβ)1–42 forming se-
nile plaques [19, 20], a hallmark of AD pathology [21].
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Increased numbers of activated microglia and elevated
levels of IL-6 mRNA have also been found in the hippo-
campus of patients with dementia with Lewy bodies
(DLB) [22], a neurodegenerative dementia disorder char-
acterised by the presence of both senile plaques and α-
synuclein occlusions [23]. Although studies investigating
the impact of IL-6 on cognitive decline in AD and pa-
tients are few, a couple of studies support the idea. An
association between increased levels of IL-6 and worse
cognitive performance has been shown in patients with
Parkinson’s disease (PD) and dementia [24] (a condition
resembling DLB in regard to neuropathological changes
and symptoms [23]) and patients with PD with cognitive
impairment [18]. Patients with mild cognitive impair-
ment (MCI), a condition associated with increased risk
of dementia [25], show improvement of cognitive func-
tion as well as reduced peripheral IL-6 and tumour ne-
crosis factor α (TNF-α) levels after repetitive physical
exercise [26]. Additionally, increased levels of periph-
eral IL-1β and TNF-α, two glia-derived proinflamma-
tory cytokines acting conjointly with IL-6 [27], have
been found to be associated with marked cognitive de-
cline in patients with AD [28, 29].
The altered brain expression of IL-6 in AD and DLB
patients and the found link between elevated peripheral
IL-6 and cognitive decline has led to studies attempting
to monitor ongoing pathological neuroinflammation by
analysing IL-6 concentration in CSF. These studies, in
particular studies on patients with AD, have led to incon-
sistent results, with reports of increased levels [30–32],
decreased levels [33] and unchanged levels [34, 35] of IL-6
in CSF.
To our knowledge, there is so far only one published
study on CSF IL-6 levels in patients with DLB. That study
showed a slight, although not significant, increase in CSF
IL-6 levels in patients with DLB compared with age-
matched controls [36]. Given this finding, together with
the previous studies demonstrating increased neuroin-
flammation in relation to senile plaque as well as the
many studies showing an impact of IL-6 on cognition, we
find it likely that IL-6 plays a role in DLB pathology. To
further investigate this hypothesis and to further ex-
plore whether DLB pathology affects CSF IL-6 levels
differently compared with AD pathology, we here com-
pared IL-6 CSF concentrations in patients with DLB, pa-
tients with AD and control subjects without dementia and
examined the potential association between the IL-6
levels and biomarkers correlating with neuropatho-
logical changes characteristic of AD and DLB. We also
examined the relationship between CSF IL-6 levels and
Mini Mental State Examination (MMSE) scores to in-
vestigate whether IL-6 may be an underlying factor in-




The study included dementia patients and control subjects
without dementia recruited through the Neurology Clinic
and the Memory Clinic at Skåne University Hospital,
Malmö, Sweden. The cohort has been described previ-
ously [37, 38]. It consisted of 36 control subjects without
dementia, 45 patients with AD and 29 patients with DLB.
The control subjects without dementia were individuals
with mild cognitive symptoms, but these symptoms were
not to the extent of a formal MCI or dementia diagnosis.
Clinical diagnoses were made according to the American
Psychiatric Association’s Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition [39], combined
with the diagnostic criteria of the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Asso-
ciation [40] for probable AD. Diagnoses of probable DLB
were made according to the DLB consensus criteria
[23, 41]. The cognitive status of the patients and the con-
trol subjects without dementia was evaluated using the
MMSE [42]. The CSF AD biomarkers (Aβ1–42, total tau
[T-tau], tau phosphorylated at threonine 181 [P-tau181])
were analysed according to clinical routine by commercial
enzyme-linked immunosorbent assay (ELISA) kits (Inno-
genetics, Ghent, Belgium). Quantification of CSF α-
synuclein levels was performed by the use of sandwich
ELISA kits (Invitrogen, Carlsbad, CA, USA) as previously
described [38, 43]. Individuals with acute or chronic in-
flammatory conditions (14 % of control subjects without
dementia, 11 % of patients with AD and 13 % of patients
with DLB) were excluded from the study. All individuals
provided their informed consent, either (1) by use of a
passive consent procedure whereby consent for retrospect-
ive use of banked clinical samples and data were assumed
if individuals did not actively retract permission, as
instructed in repeated local press advertisements; or (2) by
active written informed consent. Informed consent was
documented in two separate registries, including the pa-
tient’s medical chart, and in the local clinical research data-
base. The study protocol was approved by the local ethics
committee at Lund University and carried out in accord-
ance with the Declaration of Helsinki.
IL-6 quantification analysis
Levels of IL-6 in CSF were measured with a human proin-
flammatory 4-plex ultra-sensitive electrochemilumines-
cence immunoassay (Meso Scale Discovery, Rockville,
MD, USA). This immunoassay is designed to analyse IL-6,
interferon γ, TNF-α and IL-1β; however, only IL-6 levels
were within detection range and are therefore the only
values presented in this article. Standards and samples
were analysed in duplicates. The detection limit for IL-6
was 0.055 pg/ml.
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Statistical analysis
Statistical analysis was performed using IBM SPSS software
(version 20.0 for Windows; IBM, Armonk, NY, USA). The
Kolmogorov–Smirnov test was used to assess the normality
of distributions. The IL-6 levels were non-normally distrib-
uted within the three different groups and were therefore
transformed into logarithms before analysis. One-way ana-
lysis of variance (ANOVA), followed by the Bonferroni
post hoc correction (comparisons for n = 3), was used
for comparisons between the three patients groups.
Spearman correlation test were used for correlation be-
tween MMSE and IL-6 and the correlation between IL-
6 and AD markers as well as α-synuclein were analysed
using the Pearson correlation test. The results are pre-
sented as mean ± standard deviation. p < 0.05 was con-
sidered significant.
Results
Characteristics of individuals included in the study
The demographic data of individuals included in the study
are presented in Table 1. The number of women and men
was roughly the same in the control and DLB patient
groups, but the AD patient group consisted of more
women than men. The patients with dementia scored sig-
nificantly lower than control subjects without dementia
on the MMSE (p < 0.001). Both patients with AD and pa-
tients with DLB had significantly lower CSF levels of
Aβ1–42 than control subjects (p < 0.001 and p < 0.001,
respectively). P-tau and T-tau were significantly increased
in patients with AD (p < 0.001 and p < 0.001, respectively),
but not in patients with DLB, compared with control
subjects without dementia. Levels of α-synuclein were sig-
nificantly lower in CSF from patients with DLB than in
control subjects without dementia. The patients with AD
and patients with DLB were significantly older than con-
trol subjects without dementia (p < 0.001 and p < 0.001,
respectively), but there were no age differences between
the two patient groups.
Cerebrospinal fluid levels of IL-6 are decreased in patients
with DLB
Our first aim was to determine whether IL-6 levels are al-
tered in patients with DLB compared with patients with
AD and control subjects without dementia. Because the
IL-6 levels were not normally distributed, we transformed
the IL-6 values by taking the logarithms (log) of the data
before analysis. A multiple-comparisons analysis of log-
transformed IL-6 values revealed significant differences
between groups (p < 0.001 by ANOVA). Patients with
DLB had significantly lower log-transformed IL-6 values
than patients with AD and control subjects without de-
mentia (p < 0.001 and p = 0.002, respectively), whereas the
log-transformed IL-6 values of patients with AD did not
differ from those of control subjects without dementia
(Fig. 1a). The analysis further showed that gender had no
impact on log-transformed IL-6 values in any of the ana-
lysed groups. Although we found no relationship between
age and IL-6 levels, we considered the fact that control
subjects without dementia were significantly younger than
patients with DLB. Thus, to avoid potential biases, we
analysed the log-transformed IL-6 values with age as a co-
variate (analysis of covariance [ANCOVA]). The analysis
showed that the log-transformed IL-6 levels were still sig-
nificantly lower in patients with DLB than in patients with
AD and control subjects without dementia (p < 0.001 and
p = 0.006, respectively). Finally, we analysed CSF from a
Table 1 Characteristics of individuals included in the study
Variable Control AD DLB
Number of subjects (M/F)a 36 (16/20) 45 (13/32) 29 (12/17)
Age (yr)a 62 (44–82) 76 (61–86)*** 74 (63–84)***
MMSE (score)a 29 (26–30)b 20 (7–29)b,*** 20 (7–27)***
P-tau (ng/L)c 46.33 ± 18.37d 105.25 ± 41.76e,*** 57.96 ± 20.47f
T-tau (ng/L)c 287.68 ± 133.62g 823.10 ± 340.67f,*** 412.69 ± 169.36f
Aβ1–42 (ng/L)c 713.45 ± 213.58g 352.71 ± 101.59f,*** 457.31 ± 195.32f,***
α-Synuclein (pg/ml)c 693.61 ± 194.71 781.68 ± 222.25b,*** 585.01 ± 216.44b,**
IL-6 (pg/ml)c 1.17 ± 1.10 1.37 ± 1.09 0.90 ± 1.23**
Aβ1–42 amyloid-β peptide 1–42, AD Alzheimer’s disease, DLB dementia with Lewy bodies, IL interleukin, MMSE Mini Mental State Examination, P-tau phosphorylated
tau, T-tau total tau
aData are presented as median (range)
bData missing for one participant
cData are presented as mean ± SD
dData missing for 15 participants
eData missing for 13 participants
fData missing for three participants
gData missing for 14 participants
***Indicates a significant difference at the p < 0.001 level compared with controls
**Indicates a significant difference at the p < 0.01 level compared with controls
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randomly selected subset of individually age-matched pa-
tients with DLB and control pairs (n = 21). Values of log-
transformed IL-6 in this subset of patients with DLB were
also significantly lower than those of control subjects
without dementia (p = 0.003).
Cerebrospinal fluid levels of IL-6 correlate with MMSE and
α-synuclein in patients with DLB
Next, we analysed the association between log-transformed
IL-6 and biomarkers for AD and synucleinopathy. We
found no correlation between log-transformed IL-6 and
the AD markers Aβ1–42, P-tau and T-tau in control
subjects without dementia, patients with AD or patients
with DLB. We did, however, find a significant positive
correlation between log-transformed IL-6 and α-
synuclein in patients with DLB (r = 0.383, p = 0.048)
(Fig. 1b), but not in patients with AD or control sub-
jects without dementia. Finally, we investigated whether
log-transformed IL-6 correlates with cognitive decline
in patients with AD and patients with DLB. We de-
tected a significant negative correlation between MMSE
score and log-transformed IL-6 in patients with DLB
(r = −0.464, p = 0.01) (Fig. 1c) and a trend to significance
in patients with AD (r = −0.260, p = 0.089), but not in con-
trol subjects without dementia. Correlation analysis of the
pairwise age-matched DLB patient and control subgroup
showed that the IL-6 correlation with α-synuclein in pa-
tients with DLB stayed significant (r = 0.601, p = 0.006),
whereas the significance between IL-6 and MMSE was lost
and only a trend toward significance remained (r = −0.417,
p = 0.060).
Discussion
In line with the many previous preclinical and clinical
studies demonstrating a link between cognition and IL-6,
we show that CSF levels of IL-6 in patients with DLB sig-
nificantly and negatively correlated with MMSE score. A
similar, although not significant, association trend between
these two variables was also seen in patients with AD.
These findings indicate that increased IL-6 levels are
linked to cognitive disabilities in patients with DLB and
patients with AD and could be interpreted as further
evidence of involvement of neuroinflammatory processes
in both of these disorders. However, our results also show
that patients with DLB displayed significantly lower CSF
concentrations of IL-6 than both control subjects without
dementia and patients with AD. This result inevitably
contradicts the idea that neuroinflammatory processes, or
at least IL-6 secretion, is a prominent feature of DLB path-
ology. Interestingly, a lack of protuberant neuroinflamma-
tory processes in patients with DLB, as opposed to in
patients with AD, has been described before. As noted in
Fig. 1 Log-transformed interleukin-6 (logIL-6) levels in cerebrospinal fluid (CSF) of control subjects without dementia (Ctrl), patients with Alzheimer’s
disease (AD) and patients with dementia with Lewy bodies (DLB). a Box plot represents the mean ± standard deviation of logIL-6 levels in Ctrl, AD
and DLB. b Plot shows correlations between CSF levels of α-synuclein and logIL-6 in patients with DLB (p < 0.01). c Plot demonstrates the negative
correlation between Mini Mental State Examination (MMSE) score and logIL-6 in patients with DLB. *Significant difference at p < 0.05 level; **significant
difference at p < 0.01 level; ***significant difference at p < 0.001 level
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the Introduction section, studies imply that Aβ1–42 path-
ology underlies the altered IL-6 levels in patients with AD
because elevated expression of IL-6 has been found in
close vicinity to Aβ1–42 plaques in these patients [19, 20].
If this scenario holds true, one would expect that patients
with DLB, who frequently also have Aβ1–42 plaques, would
show elevated CSF concentration of IL-6. However, in a
previous brain tissue study, researchers compared the
amount of activated microglia in patients with AD and
patients with DLB and found that, although activated
microglia were present in all cortical regions of patients
with AD, the number of activated microglia in patients
with DLB did not differ from numbers found in control
subjects without dementia [44]. The authors of the study
pointed out that their patients with DLB, just like patients
with DLB in general [23], did not display neurofibrillary
tangles (NFT) characteristic of AD and suggested that
NFT pathology rather than Aβ1–42 pathology is the under-
lying cause of the neuroinflammatory processes in AD
[44]. This reasoning would explain the difference in IL-6
levels between patients with AD and patients with DLB in
our study, as the patients with DLB showed unaltered P-
tau concentrations (considered to be indicative of few or
no NFT), whereas the P-tau levels in the patients with AD
were significantly elevated (considered to be indicative of
NFT presence).
Quantification of IL-6 in CSF from patients with DLB
has (to our knowledge) been performed only once previ-
ously. That study, in contrast to ours, demonstrated a
slight, non-significant increase in IL-6 levels [36]. The dis-
crepancy between the previous finding and our results
could be explained by the fact that the earlier study used a
different IL-6 assay, but other variables may also be
accounted for. For example the mean MMSE score of
patients with DLB in the earlier study was lower than the
mean MMSE score in our DLB patient groups (18.0 ± 4.8
vs 20.4 ± 5.5). Admittedly, the difference in MMSE is
small, but in view of our findings demonstrating an in-
crease in IL-6 levels in patients with lower MMSE scores,
it may well be that an analysis of CSF from DLB patient
groups with lower mean MMSE scores fails to reveal a
potential disease-induced decrease in IL-6 levels. Further,
the control subjects without dementia included in our
study were significantly younger than the patients with
DLB and patients with AD, which is a limitation, particu-
larly considering that previous studies have demonstrated
an age-dependent increase of IL-6 levels in CSF [45] and
serum (for review, see [46]). However, no significant cor-
relation between age and CSF IL-6 levels was found in
our study, a finding also reported by other researchers
[17, 24, 47]. The IL-6 levels were still significantly de-
creased in patients with DLB compared with both con-
trol subjects without dementia and patients with AD
when the IL-6 values were analysed after age
adjustment (ANCOVA). In addition, the levels of IL-6
in patients with DLB were significantly lower than
those of patients with AD, who were within the same
age range as the patients with DLB. Nevertheless, to ex-
clude any potential cofounding effect of age, we se-
lected 21 age-matched DLB patient–control pairs.
Analysis of CSF from this subcohort still showed de-
creased levels of IL-6 in patients with DLB compared with
control subjects without dementia (p = 0.003). From a
clinical perspective it is important to point out that DLB
has a male preponderance [48] and that our DLB cohort
therefore should be considered atypical. However, because
levels of IL-6 were unaffected by gender in all patient
groups, we concluded that gender preponderance did not
affect the results in this study.
Further, the size of our cohorts is rather small, which un-
doubtedly is a limitation of the study. Another limitation is
the fact that we had access only to CSF from the individ-
uals included in the study and therefore were not able to
analyse IL-6 levels in serum or blood in the same individ-
uals. Indeed, a comparison of IL-6 levels in blood and CSF
could potentially indicate whether the IL-6 source is of
peripheral or brain parenchymal nature. We would there-
fore like to emphasise the importance that future ante-
mortem clinical studies on the implication of IL-6 in DLB
and AD pathology should include larger cohorts as well as
analysis of both CSF and serum and blood.
In recent years, levels of α-synuclein have been pro-
posed as a biomarker for synucleinopathy, as patients
with PD, DLB and multiple system atrophy often show
decreased CSF levels of the peptide compared with pa-
tients with AD [1, 49–53] and controls [52, 54, 55]. It
should be pointed out, however, that a couple of studies
have shown contradicting results, with patients with
DLB displaying unaltered [56, 57] or even increased [58]
levels of α-synuclein compared with patients with AD.
Additionally, in two studies researchers reported unaltered
α-synuclein levels in patients with DLB compared with
controls [49, 58], although the mean α-synuclein value in
one study was lower than in controls. The α-synuclein
values in patients with DLB included in our study were
significantly decreased, which is in line with results in the
majority of previous studies. Although the mean value of
α-synuclein in patients with AD was increased, it did not
reach significance. This discrepancy seen in our results
and others’ could be due to several factors, including diag-
nostic criteria and cohort sample sizes. The fact that all
the previously reported CSF α-synuclein studies used dif-
ferent analytical methods, including in-house ELISAs with
various antibodies, mass spectrometry and Luminex tech-
nology (Luminex, Austin, TX, USA), is most probably also
an important aspect to consider and highlights the im-
portance of finding a global ‘gold standard’ when analysing
CSF α-synuclein in the future. Nevertheless it should be
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underscored that the majority of studies, regardless of
analytical method, point towards α-synuclein as a promis-
ing biomarker for distinguishing synucleinopathies such
as DLB and PD with dementia from other forms of
dementia.
Our study shows a positive correlation between IL-6
and α-synuclein levels in CSF from patients with DLB.
This finding could be viewed from the perspective that
lowered α-synuclein concentration is thought to mirror
the synucleinopathy characteristic of entrapment of α-
synuclein in the brain parenchyma. If this hypothesis
holds true, IL-6 secretion must decrease as α-synuclein
pathology increases. Such a scenario would be in line with
our results showing decreased levels of IL-6 in patients
with DLB compared with patients with AD and control
subjects without dementia. The suggested scenario, how-
ever, inevitably also contradicts the earlier results demon-
strating activated microglia and enhanced mRNA IL-6
levels adjacent to α-synuclein occlusions in the hippocam-
pus of patients with DLB and patients with PD [22]. In
vitro studies have additionally shown increased microglial
activation [59, 60] and IL-6 secretion [59] in the presence
of α-synuclein. Moreover, studies of patients with PD,
another neurodegenerative disorder characterised by synu-
cleinopathy, display microglial activation, increased mRNA
expression of IL-6 [22, 61] and elevated CSF levels of IL-6
[30, 62]. With regard to these findings, and considering
the fact that we found increased IL-6 levels in patients
with DLB with very low MMSE scores, it is important not
to rule out the possibility that IL-6 plays a vital role in
DLB pathology. Future studies using animal and cell cul-
ture models are required, however, to fully understand the
impact of IL-6 on brain cell integrity and function in rela-
tion to DLB pathology.
Conclusions
Our study, by demonstrating lower CSF IL-6 levels as well
as a correlation between IL-6 and α-synuclein in patients
with DLB but not in patients with AD, underscores the dif-
ferences in pathological and disease mechanisms between
these two neurodegenerative dementia forms. Future stud-
ies with larger cohorts are required to ratify the potential
use of IL-6 as a clinical biomarker to distinguish DLB path-
ology from AD pathology in early dementia stages.
The negative correlation we found between IL-6 and
MMSE score in patients with DLB, as well as the tendency
toward a correlation in patients with AD, adds to the
growing evidence pointing towards a potential role of this
cytokine in cognitive alterations.
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